Upsher-Smith Showcases Innovative Rare Disease Solutions
Upsher-Smith Laboratories, LLC is making strides in the treatment of rare diseases, set to present its expanded portfolio at the upcoming Child Neurology Society (CNS) Annual Meeting. Attendees can visit their booths to discover the latest product offerings and learn more about their Promise of Support™ program.
Highlighting Recent Approvals
This year, Upsher-Smith emphasizes newly acquired products like VIGAFYDE™ (vigabatrin) Oral Solution and TORPENZ™ (everolimus) Tablets. VIGAFYDE is particularly significant as it's the first ready-to-use vigabatrin oral solution approved for treating infantile spasms in pediatric patients. This innovative product allows caregivers to administer medication without the need for reconstitution, facilitating easier treatment management for young patients.
Introducing VIGAFYDE™
VIGAFYDE offers a breakthrough in treatment for infantile spasms, a rare form of epilepsy. As the first new drug application approved for this condition in 15 years, it serves as a vital alternative for both patients and their families. Since its launch, it has quickly become a preferred choice due to its user-friendly formulation.
Expanding TORPENZ™ Access
TORPENZ, an oral mTOR inhibitor, addresses specific manifestations of Tuberous Sclerosis Complex (TSC). This medication stands out as a part of the Upsher-Smith Promise of Support™ program, providing essential resources for patients and healthcare providers. With its dual indication for both renal angiomyolipoma and subependymal giant cell astrocytoma (SEGA), TORPENZ is a crucial addition to the therapeutic landscape for TSC.
Commitment to Patient Support
Upsher-Smith demonstrates its commitment to patients and caregivers through the Promise of Support™ program. This initiative is designed to ensure that those affected by rare diseases have access to comprehensive resources throughout their treatment journey. Since its inception nearly a decade ago, the program has expanded to include assistance with medication supply, prior authorization support, and education materials for patients and families.
Safety and Monitoring Procedures
Both VIGAFYDE and TORPENZ are subject to strict monitoring protocols due to the serious side effects associated with their use. VIGAFYDE carries specific risks of permanent vision loss, necessitating thorough awareness and regular vision assessments for patients. Similarly, TORPENZ requires ongoing kidney function monitoring to mitigate possible adverse outcomes.
Looking Forward
As Upsher-Smith continues to innovate within the realm of rare disease treatments, the company prides itself on its proactive approach to expanding patient access and enhancing therapeutic options. With a focus on high-quality products and an unwavering commitment to patient care, they invite attendees at this year’s CNS meeting to engage and seek further information about their product offerings.
Frequently Asked Questions
1. What products is Upsher-Smith showcasing at the CNS meeting?
Upsher-Smith will highlight VIGAFYDE™ (vigabatrin) Oral Solution and TORPENZ™ (everolimus) Tablets, both critical treatments for rare diseases.
2. What is the significance of VIGAFYDE™?
VIGAFYDE is notable as the first ready-to-use oral solution for treating infantile spasms, offering significant convenience for caregivers.
3. How does the Promise of Support™ program help patients?
This program provides comprehensive support, including medication assistance, education materials, and prior authorization support to ease the treatment journey.
4. What are the risks associated with VIGAFYDE?
VIGAFYDE carries serious risks, including permanent vision loss, which requires careful monitoring and regular vision assessments for patients.
5. What indications does TORPENZ™ cover?
TORPENZ is indicated for adult patients with renal angiomyolipoma and pediatric patients with TSC for treating SEGA.
